U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2K.S
Molecular Weight 110.262
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM SULFIDE

SMILES

[S--].[K+].[K+]

InChI

InChIKey=DPLVEEXVKBWGHE-UHFFFAOYSA-N
InChI=1S/2K.S/q2*+1;-2

HIDE SMILES / InChI
Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula HS
Molecular Weight 33.073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Potassium is needed to maintain good health. When potassium level falls below 3.5 mmol/L, Hypokalemia is diagnosed. In case of extremely low level of potassium (lower than 2.5 mmol/L) the following symptoms are appeared: malaise and fatigue. This low level of potassium can lead to severe muscle weakness and paralysis; respiratory failure; intermittent muscle spasms. It is known, foods that are good sources of potassium and low in sodium may reduce the risk of high blood pressure and stroke. Potassium supplementation is also recommended as an adjuvant antihypertensive agent for patients with essential hypertension.

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Phase III
665
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Crystal structures of Tritrichomonasfoetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs: a structural basis for the random-in ordered-out kinetic mechanism.
2003-02-14
Delay of natural bone loss by higher intakes of specific minerals and vitamins.
2001-05
Inhibition of HIV-1 infection by zinc group metal compounds.
1999-09
Diet, genetics and hypertension.
1997-08
Mineral and water nutrition.
1991-07
Age sensitivity to organophosphate-induced delayed polyneuropathy. Biochemical and toxicological studies in developing chicks.
1991-05-15
Patents

Patents

03932629
17
03956321
16
03959289
17
03970704
18
04008269
18
04029867
16
04511731
16
04532240
16
04568497
17
04691042
16
05187175
16
05302718
20
05403930
17
05556855
19
07250518
16
07354941
42
07655666
16
08012988
16
08436001
19
08481733
20
08513268
16
08614206
16
08669361
18
08741915
18
20030186989
17
20080153836
17
20090286768
16
20100144747
17
20110251176
16
20110294818
16
20120208817
16
20130079321
16
20130203732
16
20130217666
16

Sample Use Guides

In Vivo Use Guide
Potassium is administered in various dosage forms (gluconate, citrate, chloride, bicarbonate). Exact dose should be determined by a doctor. Most people will not take more than 100 mEq a day.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:41:48 GMT 2025
Edited
by admin
on Mon Mar 31 18:41:48 GMT 2025
Record UNII
31R0R7HD0N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIPOTASSIUM MONOSULFIDE
Preferred Name English
POTASSIUM SULFIDE
HSDB   INCI   MI   WHO-DD  
INCI  
Official Name English
POTASSIUM SULPHIDE (2:1)
Common Name English
POTASSIUM SULFIDE [MI]
Common Name English
DIPOTASSIUM MONOSULPHIDE
Common Name English
POTASSIUM SULFIDE [HSDB]
Common Name English
POTASSIUM SULFIDE (2:1)
Common Name English
POTASSIUM MONOSULPHIDE
Common Name English
Potassium sulfide [WHO-DD]
Common Name English
POTASSIUM SULPHIDE
Common Name English
POTASSIUM MONOSULFIDE
Common Name English
Code System Code Type Description
MERCK INDEX
m9064
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
215-197-0
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
WIKIPEDIA
POTASSIUM SULFIDE
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
DAILYMED
31R0R7HD0N
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
RXCUI
236907
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY RxNorm
FDA UNII
31R0R7HD0N
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID901014376
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
EVMPD
SUB14996MIG
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
HSDB
1204
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
PUBCHEM
162263
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
CAS
1312-73-8
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
SMS_ID
100000078865
Created by admin on Mon Mar 31 18:41:48 GMT 2025 , Edited by admin on Mon Mar 31 18:41:48 GMT 2025
PRIMARY
Related Record Type Details
Structure of HYDROGEN SULFIDE
PARENT -> SALT/SOLVATE
Structure of POTASSIUM SULFIDE PENTAHYDRATE
SOLVATE->ANHYDROUS
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966